MetseraMTSR got a positive adjustment to its Relative Strength (RS) Rating, from 88 to 93.Please watch the video at Investors ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 11 Hot New Stocks to Invest in Now. On June 22, Metsera, Inc. (NASDAQ:MTSR) ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its ...

Metsera, Inc. presents four studies on GLP-1 receptor agonist MET-097i at the ADA conference, showcasing clinical and preclinical data. Quiver AI Summary ...

View Metsera, Inc. MTSR stock quote prices, financial information, real-time forecasts, and company news from CNN.

The newly listed clinical-stage biotechnology company, Metsera Inc. MTSR rose 15.01% on Monday as the broader markets declined. What Happened: While the company reported insider trades over the ...

Metsera’s GLP-1 drug has potential for monthly dosing. This morning, Metsera, a new obesity biotech, reported that its GLP-1 drug led to substantial and durable weight loss in a Phase 1 study.

Metsera, a biotech focused on obesity drugs that came out of stealth this year, said Tuesday that it is partnering with drug manufacturer Amneal Pharmaceuticals to produce injectable and oral ...

Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Jono Emmett ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential.Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog ...